Evidence map›Paper›PMID 36589283›Full record

ArticleFrontiers in cellular neuroscience2022

Francesca Massenzio, Marco Cambiaghi, Federica Marchiotto, Diana Boriero, Cristina Limatola, Giuseppina D'Alessandro, Mario Buffelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Transcriptional Repression of CCL2 by KInternational journal of molecular sciences · 2025
    Article
  4. Calcium channels as pharmacological targets for cancer therapy.Clinical and experimental medicine · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francesca MassenzioDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Marco CambiaghiDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Federica MarchiottoDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Diana BorieroDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Cristina LimatolaDepartment of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
Giuseppina D'AlessandroDepartment of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
Mario BuffelliDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor associated macrophages (TAMs) are the mostprevalent cells recruited in the tumor microenvironment (TME). Once recruited, TAMs acquire a pro-tumor phenotype characterized by a typical morphology: ameboid in the tumor core and with larger soma and thick branches in the tumor periphery. Targeting TAMs by reverting them to an anti-tumor phenotype is a promising strategy for cancer immunotherapy. Taking advantage of Cx3cr1

Indexed as

Ca2+ activated K+ channelsimmune cells in the gliomaTRAM-34tumor associated macrophages (TAMs)two-photon imaging

Identifiers

PMID36589283
PMCPMC9798303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.